FDA adds warning for GLP-1 drugs over rare eye condition

The U.S. Food and Drug Administration announced on Nov. 9, 2026 that GLP-1 drugs must carry a warning about a possible link to non-arteritic anterior ischemic optic neuropathy (NAION), an injury to the optic nerve sometimes described as a "stroke of the eye."

NAION is caused by a sudden reduction in blood flow to the optic nerve and can lead to painless blurry vision, dark patches, partial loss of vision or blindness, often persisting as permanent impairment. Symptoms typically appear upon waking, when blood pressure is lower.

The FDA’s assessment combined data from 126 randomized controlled trials involving 134,253 participants and a review of its sentinel safety programs. The trials showed an incidence of 6.4 cases per 100,000 person-years for GLP-1 users versus 3.8 for comparators, equating to an excess of 2.6 cases per 100,000. A separate real-world analysis found 32 cases per 100,000 for GLP-1 drugs compared with 26 per 100,000 for DPP-4 inhibitors, a difference of six cases per 100,000.

Independent studies have reported similar associations. One investigation of nearly 600,000 U.S. veterans with type 2 diabetes found roughly 390 cases per 100,000 among GLP-1 users versus 290 per 100,000 for other medications, suggesting about 100 additional cases per 100,000 patients. The increased risk appears across the GLP-1 class rather than being confined to a single product.

European regulators reached a comparable conclusion in 2025 for semaglutide, labeling the condition as a very rare side effect. Experts say the risk, while real, remains low and should not deter patients from using GLP-1 drugs for approved indications such as diabetes or obesity, provided clinicians discuss the potential warning and educate patients on NAION symptoms.